Hims & Hers Health, Inc. (NYSE:HIMS) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) have been given a consensus recommendation of “Hold” by the seventeen brokerages that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, eight have assigned a hold recommendation and eight have given a buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $24.80.

Several research firms have issued reports on HIMS. Deutsche Bank Aktiengesellschaft lifted their price target on Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research note on Wednesday, November 6th. Needham & Company LLC lifted their target price on Hims & Hers Health from $28.00 to $31.00 and gave the company a “buy” rating in a research report on Monday. Piper Sandler upped their price target on Hims & Hers Health from $21.00 to $24.00 and gave the stock a “neutral” rating in a research report on Monday. Canaccord Genuity Group raised their price target on shares of Hims & Hers Health from $28.00 to $38.00 and gave the stock a “buy” rating in a research note on Monday, December 2nd. Finally, Bank of America lowered shares of Hims & Hers Health from a “buy” rating to an “underperform” rating and cut their price objective for the stock from $32.00 to $18.00 in a research report on Thursday, November 14th.

Insider Activity

In other news, CFO Oluyemi Okupe sold 269,739 shares of the company’s stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $20.31, for a total value of $5,478,399.09. Following the transaction, the chief financial officer now owns 145,763 shares of the company’s stock, valued at approximately $2,960,446.53. This represents a 64.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Soleil Boughton sold 2,339 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $20.41, for a total value of $47,738.99. Following the sale, the insider now directly owns 172,274 shares of the company’s stock, valued at approximately $3,516,112.34. The trade was a 1.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,333,446 shares of company stock valued at $34,175,197 over the last three months. Insiders own 17.71% of the company’s stock.

Hedge Funds Weigh In On Hims & Hers Health

Institutional investors and hedge funds have recently modified their holdings of the business. Main Management ETF Advisors LLC acquired a new stake in shares of Hims & Hers Health during the 3rd quarter worth $672,000. Robeco Institutional Asset Management B.V. acquired a new stake in Hims & Hers Health during the third quarter worth about $604,000. Carnegie Investment Counsel bought a new position in Hims & Hers Health in the 3rd quarter valued at about $5,531,000. Royce & Associates LP increased its holdings in Hims & Hers Health by 17.0% in the 3rd quarter. Royce & Associates LP now owns 341,000 shares of the company’s stock valued at $6,281,000 after buying an additional 49,500 shares during the period. Finally, Versor Investments LP acquired a new position in shares of Hims & Hers Health in the 3rd quarter valued at approximately $634,000. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Hims & Hers Health Stock Performance

HIMS opened at $25.74 on Friday. The firm’s fifty day moving average is $27.11 and its two-hundred day moving average is $21.62. The firm has a market cap of $5.62 billion, a PE ratio of 58.50 and a beta of 1.31. Hims & Hers Health has a twelve month low of $8.14 and a twelve month high of $35.02.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.26. The business had revenue of $401.56 million for the quarter, compared to analysts’ expectations of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. Hims & Hers Health’s revenue for the quarter was up 77.1% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.04) EPS. Equities analysts forecast that Hims & Hers Health will post 0.29 EPS for the current fiscal year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.